Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

NYU Langone offers vascular-targeted photodynamic therapy for localized prostate cancer

28.07.2010
NYU Langone Medical Center has begun a clinical trial offering vascular-targeted photodynamic therapy to patients with localized prostate cancer. This novel, minimally invasive procedure uses a light-activated drug to deliver light energy waves by way of laser fibers in order to destroy prostate cancer cells.

"This minimally invasive technique for localized prostate cancer offers the potential to destroy the cancer without making any incision or causing any potentially devastating sexual, urinary or reproductive side-effects," said Samir S. Taneja, MD, The James M. Neissa and Janet Riha Neissa Associate Professor of Urologic Oncology and director of the Division of Urologic Oncology at NYU Langone Medical Center and principal investigator for the national, multi-center clinical trial testing this technology. "This procedure only treats the cancerous part of the prostate gland, similar to how a lumpectomy might be done for breast cancer.

Photodynamic therapy is just one of the many personalized treatment options offered by the Smilow Comprehensive Prostate Cancer Center at NYU Langone Medical Center. The Center offers a wide range of the latest treatment options for prostate cancer including: open or robotic prostatectomy surgery, brachytherapy, external beam radiation therapy, cryotherapy and high-intensity focused ultrasound (HIFU), a focal therapy that uses high-energy sound waves to treat prostate cancer, now also in clinical trials at the medical center.

This Phase I/II photodynamic therapy trial is open to men diagnosed with localized prostate cancer -- determined by a needle biopsy and advanced imaging techniques -- who have chosen active surveillance, also known as "watchful-waiting. During the procedure, laser fibers are positioned over the prostate where cancer cells have been identified. Once in place, a photosensitizing drug called WST11 is administered to the patient intravenously and circulates throughout the blood stream for ten-minutes. The laser fibers are then activated to deliver a specific wavelength of light to the prostate for twenty-minutes. When the light comes into contact with the drug in circulation, the laser fibers destroy the blood vessels around the tumor shutting down the blood supply to the cancer. Patients are followed for a year after treatment with PSA tests after each visit and an MRI and needle biopsy performed at six months.

"Focal treatment of prostate cancer with techniques such as photodynamic therapy is an emerging paradigm since the over treatment of prostate cancer is a major concern for both physicians and patients," said Dr. Taneja who is also a member of the NYU Cancer Institute.

Recent European studies show photodynamic therapy successfully treats localized prostate cancer with minimal side effects. This study will investigate optimal dosage of the photosensitive drug and light-energy waves and measure outcomes of patients as well as long-term cancer control. Researchers believe the technology has the potential to treat any early stage prostate cancer as well as tumors in other organs of the body.

About NYU Langone Medical Center

NYU Langone Medical Center is one of the nation's premier centers of excellence in healthcare, biomedical research, and medical education. For over 170 years, NYU physicians and researchers have made countless contributions to the practice and science of health care. Today the Medical Center consists of NYU School of Medicine, including the Smilow Research Center, the Skirball Institute of Biomolecular Medicine, and the Sackler Institute of Graduate Biomedical Sciences; and the NYU Hospitals Center, including Tisch Hospital, a 705-bed acute-care general hospital, Rusk Institute of Rehabilitation Medicine, the first and largest facility of its kind, and NYU Hospital for Joint Diseases, a leader in musculoskeletal care, a Clinical Cancer Center and numerous ambulatory sites.

Lauren Woods | EurekAlert!
Further information:
http://www.nyumc.org

More articles from Medical Engineering:

nachricht Potentially life-saving health monitor technology designed by Sussex University physicists
10.01.2018 | University of Sussex

nachricht 2 million euros in funding for new MR-compatible electrophysiological brain implants
18.12.2017 | Max-Planck-Institut für biologische Kybernetik

All articles from Medical Engineering >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

Im Focus: A thermometer for the oceans

Measurement of noble gases in Antarctic ice cores

The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Morbid Obesity: Gastric Bypass and Sleeve Gastrectomy Are Comparable

17.01.2018 | Health and Medicine

Researchers identify new way to unmask melanoma cells to the immune system

17.01.2018 | Health and Medicine

Genetic discovery may help better identify children at risk for type 1 diabetes

17.01.2018 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>